Efavirenz-based antiretroviral therapy

HIV-positive smokers taking efavirenz had significantly faster nicotine metabolism (higher NMR) than those not taking efavirenz in a multiple regression model, with efavirenz alone accounting for 5% u

Effect: decline; b = 0.221, p = .010

HIV-positive smokers taking efavirenz had significantly faster nicotine metabolism (higher NMR) than those not taking efavirenz in a multiple regression model, with efavirenz alone accounting for 5% u

Effect: decline; b = 0.221, p = .010

HIV-positive smokers taking efavirenz had significantly faster nicotine metabolism (higher NMR) than those not taking efavirenz in a multiple regression model, with efavirenz alone accounting for 5% u

Effect: decline; b = 0.221, p = .010

HIV-positive smokers taking efavirenz had significantly faster nicotine metabolism (higher NMR) than those not taking efavirenz in a multiple regression model, with efavirenz alone accounting for 5% u

Effect: decline; b = 0.221, p = .010

HIV-positive smokers taking efavirenz had significantly faster nicotine metabolism (higher NMR) than those not taking efavirenz in a multiple regression model, with efavirenz alone accounting for 5% u

Effect: decline; b = 0.221, p = .010

HIV-positive smokers taking efavirenz had significantly faster nicotine metabolism (higher NMR) than those not taking efavirenz in a multiple regression model, with efavirenz alone accounting for 5% u

Effect: decline; b = 0.221, p = .010

HIV-positive smokers taking efavirenz had significantly faster nicotine metabolism (higher NMR) than those not taking efavirenz in a multiple regression model, with efavirenz alone accounting for 5% u

Effect: decline; b = 0.221, p = .010

HIV-positive smokers taking efavirenz had significantly faster nicotine metabolism (higher NMR) than those not taking efavirenz in a multiple regression model, with efavirenz alone accounting for 5% u

Effect: decline; b = 0.221, p = .010

HIV-positive smokers taking efavirenz had significantly faster nicotine metabolism (higher NMR) than those not taking efavirenz in a multiple regression model, with efavirenz alone accounting for 5% u

Effect: decline; b = 0.221, p = .010

HIV-positive smokers taking efavirenz had significantly faster nicotine metabolism (higher NMR) than those not taking efavirenz in a multiple regression model, with efavirenz alone accounting for 5% u

Effect: decline; b = 0.221, p = .010

HIV-positive smokers taking efavirenz had significantly faster nicotine metabolism (higher NMR) than those not taking efavirenz in a multiple regression model, with efavirenz alone accounting for 5% u

Effect: decline; b = 0.221, p = .010

HIV-positive smokers taking efavirenz had significantly faster nicotine metabolism (higher NMR) than those not taking efavirenz in a multiple regression model, with efavirenz alone accounting for 5% u

Effect: decline; b = 0.221, p = .010

HIV-positive smokers taking efavirenz had significantly faster nicotine metabolism (higher NMR) than those not taking efavirenz in a multiple regression model, with efavirenz alone accounting for 5% u

Effect: decline; b = 0.221, p = .010

HIV-positive smokers taking efavirenz had significantly faster nicotine metabolism (higher NMR) than those not taking efavirenz in a multiple regression model, with efavirenz alone accounting for 5% u

Effect: decline; b = 0.221, p = .010

HIV-positive smokers taking efavirenz had significantly faster nicotine metabolism (higher NMR) than those not taking efavirenz in a multiple regression model, with efavirenz alone accounting for 5% u

Effect: decline; b = 0.221, p = .010

HIV-positive smokers taking efavirenz had significantly faster nicotine metabolism (higher NMR) than those not taking efavirenz in a multiple regression model, with efavirenz alone accounting for 5% u

Effect: decline; b = 0.221, p = .010

HIV-positive smokers taking efavirenz had significantly faster nicotine metabolism (higher NMR) than those not taking efavirenz in a multiple regression model, with efavirenz alone accounting for 5% u

Effect: decline; b = 0.221, p = .010

HIV-positive smokers taking efavirenz had significantly faster nicotine metabolism (higher NMR) than those not taking efavirenz in a multiple regression model, with efavirenz alone accounting for 5% u

Effect: decline; b = 0.221, p = .010

HIV-positive smokers taking efavirenz had significantly faster nicotine metabolism (higher NMR) than those not taking efavirenz in a multiple regression model, with efavirenz alone accounting for 5% u

Effect: decline; b = 0.221, p = .010

HIV-positive smokers taking efavirenz had significantly faster nicotine metabolism (higher NMR) than those not taking efavirenz in a multiple regression model, with efavirenz alone accounting for 5% u

Effect: decline; b = 0.221, p = .010

HIV-positive smokers taking efavirenz had significantly faster nicotine metabolism (higher NMR) than those not taking efavirenz in a multiple regression model, with efavirenz alone accounting for 5% u

Effect: decline; b = 0.221, p = .010

HIV-positive smokers taking efavirenz had significantly faster nicotine metabolism (higher NMR) than those not taking efavirenz in a multiple regression model, with efavirenz alone accounting for 5% u

Effect: decline; b = 0.221, p = .010

HIV-positive smokers taking efavirenz had significantly faster nicotine metabolism (higher NMR) than those not taking efavirenz in a multiple regression model, with efavirenz alone accounting for 5% u

Effect: decline; b = 0.221, p = .010

HIV-positive smokers taking efavirenz had significantly faster nicotine metabolism (higher NMR) than those not taking efavirenz in a multiple regression model, with efavirenz alone accounting for 5% u

Effect: decline; b = 0.221, p = .010

HIV-positive smokers taking efavirenz had significantly faster nicotine metabolism (higher NMR) than those not taking efavirenz in a multiple regression model, with efavirenz alone accounting for 5% u

Effect: decline; b = 0.221, p = .010

HIV-positive smokers taking efavirenz had significantly faster nicotine metabolism (higher NMR) than those not taking efavirenz in a multiple regression model, with efavirenz alone accounting for 5% u

Effect: decline; b = 0.221, p = .010

HIV-positive smokers taking efavirenz had significantly faster nicotine metabolism (higher NMR) than those not taking efavirenz in a multiple regression model, with efavirenz alone accounting for 5% u

Effect: decline; b = 0.221, p = .010